Drug intelligence / Profile preview

GSK3528869A

Development stage: Phase 2
Lead developer: GSK
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK3528869A is an investigational therapeutic vaccine developed for the treatment of chronic hepatitis B infection. It is a three-component vaccine comprising (1) ChAd155-hIi-HBV, a replication-defective simian adenovirus vector encoding truncated hepatitis B core antigen (HBcAg) and full-length small hepatitis B surface antigen (S-HBsAg); (2) MVA-HBV, a modified vaccinia Ankara virus encoding the same HBV antigens; and (3) HBc-HBs/AS01B-4, which includes these antigens enhanced by the AS01B-4 adjuvant—a liposomal combination of 3-O-desacyl-4'-monophosphoryl lipid A and QS-21 saponin. The vaccine aims to stimulate robust immune responses against HBV antigens in patients with chronic hepatitis B, potentially enabling better viral control or clearance[2][1][7]. It is being developed by GSK and has been studied in sequential regimens with bepirovirsen, an antisense oligonucleotide targeting HBV RNA[5].

Other names: GSK chronic hepatitis B vaccine

Targets

HBsAg (Hepatitis B surface antigen)HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on GSK3528869A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3528869A.

Explore the full profile